UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Nicotine as a potential neuroprotective agent for Parkinson's disease

Movement disorders, 2012-07, Vol.27 (8), p.947-957

2012

Link zum Volltext

Verfügbarkeit prüfen

Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

Movement disorders, 2017-04, Vol.32 (4), p.538-548

2017

Link zum Volltext

Verfügbarkeit prüfen

Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias

Neurobiology of disease, 2016-07, Vol.91, p.47-58

2016

Link zum Volltext

Verfügbarkeit prüfen

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease

The Journal of pharmacology and experimental therapeutics, 2008-10, Vol.327 (1), p.239

2008

Link zum Volltext

Verfügbarkeit prüfen

The Inferior Colliculus in Alcoholism and Beyond

Frontiers in systems neuroscience, 2020-12, Vol.14, p.606345-606345

2020

Link zum Volltext

Verfügbarkeit prüfen

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Nicotine & tobacco research, 2019-02, Vol.21 (3), p.357-369

2019

Link zum Volltext

Verfügbarkeit prüfen

Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia

Experimental neurology, 2016-12, Vol.286, p.32-39

2016

Link zum Volltext

Verfügbarkeit prüfen

Nicotinic receptors as CNS targets for Parkinson's disease

Biochemical pharmacology, 2007-10, Vol.74 (8), p.1224-1234

2007

Link zum Volltext

Verfügbarkeit prüfen

Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization

The Journal of pharmacology and experimental therapeutics, 2010-06, Vol.333 (3), p.929

2010

Link zum Volltext

Verfügbarkeit prüfen

Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats

The Journal of pharmacology and experimental therapeutics, 2012-03, Vol.340 (3), p.612

2012

Link zum Volltext

Verfügbarkeit prüfen

Nicotine-mediated improvement in l -dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function

Neurobiology of disease, 2013-02, Vol.50, p.30-41

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeting nicotinic receptors for Parkinson's disease therapy

CNS & neurological disorders drug targets, 2011-09, Vol.10 (6), p.651

2011

Link zum Volltext

Verfügbarkeit prüfen

Including garlic in the diet may help lower blood glucose, cholesterol, and triglycerides

The Journal of nutrition, 2006-03, Vol.136 (3S), p.800S-802S

2006

Link zum Volltext

Verfügbarkeit prüfen

Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease

Biochemical pharmacology, 2015-10, Vol.97 (4), p.399-407

2015

Link zum Volltext

Verfügbarkeit prüfen

Subunit Composition of Nicotinic Receptors in Monkey Striatum: Effect of Treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA

Molecular pharmacology, 2005-01, Vol.67 (1), p.32-41

2005

Link zum Volltext

Verfügbarkeit prüfen

Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias

The European journal of neuroscience, 2019-03, Vol.49 (6), p.859-868

2019

Link zum Volltext

Verfügbarkeit prüfen

Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine

The Journal of pharmacology and experimental therapeutics, 2006-10, Vol.319 (1), p.285

2006

Link zum Volltext

Verfügbarkeit prüfen

Role for the nicotinic cholinergic system in movement disorders; therapeutic implications

Pharmacology & therapeutics (Oxford), 2014-10, Vol.144 (1), p.50-59

2014

Link zum Volltext

Verfügbarkeit prüfen

Varenicline is a potent partial agonist at α6β2 nicotinic acetylcholine receptors in rat and monkey striatum

The Journal of pharmacology and experimental therapeutics, 2012-08, Vol.342 (2), p.327

2012

Link zum Volltext

Verfügbarkeit prüfen

α6β2 and α4β2 Nicotinic Receptors Both Regulate Dopamine Signaling with Increased Nigrostriatal Damage: Relevance to Parkinson's Disease

Molecular pharmacology, 2010-11, Vol.78 (5), p.971-980

2010

Link zum Volltext

Verfügbarkeit prüfen

Nigrostriatal Damage Preferentially Decreases a Subpopulation of α6β2 nAChRs in Mouse, Monkey, and Parkinson's Disease Striatum

Molecular pharmacology, 2007-07, Vol.72 (1), p.52-61

2007

Link zum Volltext

Verfügbarkeit prüfen

Multiple roles for nicotine in Parkinson's disease

Biochemical pharmacology, 2009-10, Vol.78 (7), p.677-685

2009

Link zum Volltext

Verfügbarkeit prüfen

The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions

Experimental neurology, 2015-01, Vol.263, p.277-284

2015

Link zum Volltext

Verfügbarkeit prüfen

The alpha 7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions

Experimental neurology, 2015-01, Vol.263, p.277-284

2015

Link zum Volltext

Verfügbarkeit prüfen

Striatal cholinergic interneurons regulate L-dopa-induced dyskinesias

Biochemical pharmacology, 2015-10, Vol.97 (4), p.630-630

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nicotine as a potential neuroprotective agent for Parkinson's disease

Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease

The Inferior Colliculus in Alcoholism and Beyond

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia

Nicotinic receptors as CNS targets for Parkinson's disease

Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization

Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats

Nicotine-mediated improvement in l -dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function

Targeting nicotinic receptors for Parkinson's disease therapy

Including garlic in the diet may help lower blood glucose, cholesterol, and triglycerides

Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease

Subunit Composition of Nicotinic Receptors in Monkey Striatum: Effect of Treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA

Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias

Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine

Role for the nicotinic cholinergic system in movement disorders; therapeutic implications

Varenicline is a potent partial agonist at α6β2 nicotinic acetylcholine receptors in rat and monkey striatum

α6β2 and α4β2 Nicotinic Receptors Both Regulate Dopamine Signaling with Increased Nigrostriatal Damage: Relevance to Parkinson's Disease

Nigrostriatal Damage Preferentially Decreases a Subpopulation of α6β2 nAChRs in Mouse, Monkey, and Parkinson's Disease Striatum

Multiple roles for nicotine in Parkinson's disease

The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions

The alpha 7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions

Striatal cholinergic interneurons regulate L-dopa-induced dyskinesias

Suchergebnisse filtern